Sagent launches drug for apnea of prematurity in infants

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a drug used to treat apnea of prematurity in infants, the drug maker said Wednesday.

Sagent announced the launch of caffeine citrate injection and caffeine citrate oral solution, used to treat apnea of prematurity in infants between 28 and less than 33 weeks gestational age.

The market for the drug was worth about $28.5 million during the 12-month period ended in July, according to IMS Health. The drug features Sagent's PreventIV Measures packaging and labeling, which are designed to reduce medication errors.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.